Business Impact of the COVID-19 Pandemic
First written in FY2020. 3 of 8 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2024-Q2RestatedAnnual report
「Regarding the impact of COVID-19, we expect that it will take some time for the situation to subside, but have determined that its impact on our group’s business performance is minor. Accordingly, as stated in the additional information section of the annual securities report for the previous consolidated fiscal year, there is no impact on accounting estimates.」
Regarding COVID-19, it reconfirmed its view that the impact on business performance was minor and there was no impact on accounting estimates. - FY2023-Q2RestatedAnnual report
「Regarding the impact of COVID-19, we expect that it will take some time for the situation to subside, but have determined that its impact on our group’s business performance is minor. Accordingly, as stated in the additional information section of the annual securities report for the previous consolidated fiscal year, there is no impact on accounting estimates.」
Regarding COVID-19, it reconfirmed its view that although it would take some time for the situation to subside, the impact on business performance was minor and there was no impact on accounting estimates. - FY2022-Q2RestatedAnnual report
「Regarding the impact of COVID-19, we expect that it will take some time for the situation to subside, but have determined that its impact on our group’s business performance is minor. Accordingly, as stated in the additional information section of the annual securities report for the previous consolidated fiscal year, there is no impact on accounting estimates.」
Regarding COVID-19, it reconfirmed its view that although it would take some time for the situation to subside, the impact on business performance was minor and there was no impact on accounting estimates. - FY2021MitigatedAnnual report
「Although 6 infected people had been identified as of the date of preparation of this document, all business activities, including research and development and production, were operating normally.」
The risk materialised when 6 employees were confirmed to be infected, but business activities, including research and development and production, continued to operate normally through measures such as working from home, mask-wearing, temperature checks and antigen testing. No delays to clinical trials or similar impacts had materialised. - FY2021-Q3MaterialisedAnnual report
「As of the present time, our group has not been affected by COVID-19, except that the timing of recognition of contract consideration has been pushed back to the fourth quarter of the consolidated fiscal year.」
COVID-19 resulted in the timing of recognition of contract consideration under the out-licensing agreement for a lysosomal disease therapeutic enzyme product being pushed back to the fourth quarter. The company explained that it had not been affected in any other way. - FY2021-Q2MaterialisedAnnual report
「As of the present time, our group has not been affected by COVID-19, except that the timing of recognition of contract consideration has been pushed back to the third quarter of the consolidated fiscal year or later.」
COVID-19 made face-to-face negotiations difficult, resulting in the timing of recognition of contract consideration under the out-licensing agreement for a lysosomal disease therapeutic enzyme product being pushed back to the third quarter or later. - FY2021-Q1SoftenedAnnual report
「Regarding the impact of COVID-19, we expect that it will take some time for the situation to subside, but have determined that its impact on our group’s business performance is minor. Accordingly, as stated in the additional information section of the annual securities report for the previous consolidated fiscal year, there is no impact on accounting estimates.」
While expecting that it would take some time for the pandemic to subside, the group determined that it had not been affected as of the quarter-end, that the impact on business performance was minor, and that there was no impact on accounting estimates. - FY2020First statedAnnual report
「As of the date of preparation of this report, there was no clear prospect of the COVID-19 pandemic coming to an end, and the outlook remained uncertain.」
The COVID-19 pandemic was first identified as a standalone business risk. The company cited potential impacts on research and production activities from employee infections, delays to clinical trials, and the supply of human bone marrow fluid imported from the United States, but stated that no impacts had materialised as of the filing date.